| 产品名称： | Clostridium perfringens (Veillon and Zuber) Hauduroy et al. |
|---|---|
| 商品货号： | TS154860 |
| Strain Designations： | LNG11 |
| Application： | Produces antineoplastic agents |
| Isolation： | Derived from Clostridium perfringens strain Lechien |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Storage Conditions： | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Preceptrol®： | no |
| Type Strain： | no |
| Comments： | Type A The presence of cpa, cpb2, and pfoA genes was confirmed by PCR. This strain does not produce epsilon toxin |
| Toxins： | This strain does not produce epsilon toxin. |
| Medium： | ATCC® Medium 1053: Reinforced Clostridial medium (Oxoid CM149) ATCC® Medium 2107: Modified Reinforced Clostridial ATCC® Medium 260: Trypticase soy agar/broth with defibrinated sheep blood |
| Growth Conditions： | Temperature: 37°C Atmosphere: Anaerobic |
| Name of Depositor： | JR Lapointe |
| References： | La Pointe JR, Fredette V. Anti-tumor product of bacterial origin. US Patent 3,936,354 dated Feb 3 1976 Lapointe JR, Fredette V. Nitrosoguanidine-induced attenuated Clostridium perfringens type A mutant in gas gangrene. Can. J. Microbiol. 21: 1259-1269, 1975. PubMed: 169977 Lapointe JR, Fredette V. Principle and new media for sporulation of Clostridium perfringens. Preliminary results with an attenuated mutant Union Med. Can. 104(4): 527-538, 1975. PubMed: 178082 Lapointe JR, Fredette V. Analysis of the oncolytic properties of Clostridium perfringens. Use of an attenuated mutant and Ehrlich solid carcinoma Union Med. Can. 104(7): 1070-1077, 1975. PubMed: 169620 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Clostridium perfringens (Veillon and Zuber) Hauduroy et al. |
|---|---|
| 商品货号： | TS154860 |
| Strain Designations： | LNG11 |
| Application： | Produces antineoplastic agents |
| Isolation： | Derived from Clostridium perfringens strain Lechien |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Storage Conditions： | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Preceptrol®： | no |
| Type Strain： | no |
| Comments： | Type A The presence of cpa, cpb2, and pfoA genes was confirmed by PCR. This strain does not produce epsilon toxin |
| Toxins： | This strain does not produce epsilon toxin. |
| Medium： | ATCC® Medium 1053: Reinforced Clostridial medium (Oxoid CM149) ATCC® Medium 2107: Modified Reinforced Clostridial ATCC® Medium 260: Trypticase soy agar/broth with defibrinated sheep blood |
| Growth Conditions： | Temperature: 37°C Atmosphere: Anaerobic |
| Name of Depositor： | JR Lapointe |
| References： | La Pointe JR, Fredette V. Anti-tumor product of bacterial origin. US Patent 3,936,354 dated Feb 3 1976 Lapointe JR, Fredette V. Nitrosoguanidine-induced attenuated Clostridium perfringens type A mutant in gas gangrene. Can. J. Microbiol. 21: 1259-1269, 1975. PubMed: 169977 Lapointe JR, Fredette V. Principle and new media for sporulation of Clostridium perfringens. Preliminary results with an attenuated mutant Union Med. Can. 104(4): 527-538, 1975. PubMed: 178082 Lapointe JR, Fredette V. Analysis of the oncolytic properties of Clostridium perfringens. Use of an attenuated mutant and Ehrlich solid carcinoma Union Med. Can. 104(7): 1070-1077, 1975. PubMed: 169620 |
